Neuromuscular Junction Abnormalities in Mitochondrial Disease
An Observational Cohort Study
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective To determine the prevalence of neuromuscular junction (NMJ) abnormalities in patients with mitochondrial disease.
Methods Eighty patients with genetically proven mitochondrial disease were recruited from a national center for mitochondrial disease in the United Kingdom. Participants underwent detailed clinical and neurophysiologic testing including single-fiber electromyography.
Results The overall prevalence of neuromuscular transmission defects was 25.6%. The highest prevalence was in patients with pathogenic dominant RRM2B variants (50%), but abnormalities were found in a wide range of mitochondrial genotypes. The presence of NMJ abnormalities was strongly associated with coexistent myopathy, but not with neuropathy. Furthermore, 15% of patients with NMJ abnormality had no evidence of either myopathy or neuropathy.
Conclusions NMJ transmission defects are common in mitochondrial disease. In some patients, NMJ dysfunction occurs in the absence of obvious pre- or post-synaptic pathology, suggesting that the NMJ may be specifically affected.
Footnotes
Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/cp.
The Article Processing Charge was funded by the Wellcome Trust.
- Received April 25, 2019.
- Accepted November 18, 2019.
- Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Clozapine-induced myotoxicity in patients with chronic psychotic disordersS. N. Scelsa, D. M. Simpson, H. L. McQuistion et al.Neurology, December 01, 1996 -
Articles
Adult cases of mitochondrial DNA depletion due to TK2 defectAn expanding spectrumA. Béhin, C. Jardel, K.G. Claeys et al.Neurology, February 15, 2012 -
Article
Fibroblast growth factor 21 is a sensitive biomarker of mitochondrial diseaseRyan L. Davis, Christina Liang, Fabienne Edema-Hildebrand et al.Neurology, October 18, 2013 -
Brief Communications
Pure myopathy associated with a novel mitochondrial tRNA gene mutationH. Swalwell, M. Deschauer, H. Hartl et al.Neurology, February 13, 2006